Kanabo

Drug-delivery Platform for Medical Cannabis

Health Tech & Life Sciences
Public on LSE on Feb, 2021<br>

Company Overview

Snapshot

Founded in October 2016 by Avihu Tamir, Kanabo operates with 11–50 employees. The company has raised $500,000 across one funding round. Kanabo became publicly listed on the LSE in February 2021 following a reverse merger with Spinnaker Opportunities.

Business overview

Kanabo is a Health Tech & Life Sciences company focused on the medical cannabis industry. The company develops formulations of medical cannabis extracts for vaporization, designed to work synergistically with its medically certified VapePod vaporizer platform. This drug-device combination aims to deliver patent-pending formulations with precision and consistency to treat specific ailments. Kanabo serves markets in Europe, North America, the United Kingdom, and Germany, operating within the Pharmaceuticals sector, specifically in Drug Delivery and Medical Cannabis.

Strategic signal

In October 2021, Kanabo announced a partnership with Medocann Group to exclusively develop and distribute unique cannabis strains and products for the UK and German markets. This collaboration signals Kanabo's strategic expansion into key European medical cannabis markets, leveraging partnerships to enhance product development and market penetration, which is crucial for growth in the highly regulated cannabis industry.

Company Intelligence Q&A

When did Kanabo become a public company?
Kanabo became public on the LSE in February 2021 through a reverse merger with Spinnaker Opportunities.
What significant partnership did Kanabo announce in October 2021?
In October 2021, Kanabo announced a partnership with Medocann Group to exclusively develop and distribute unique cannabis strains and products for the UK and German markets.
What was the nature of Kanabo's partnership with TILT Holdings?
In November 2020, TILT Holdings announced an expanded partnership with Kanabo Research to develop a new, medically certified inhalation device.
What strategic move did Kanabo make in February 2022?
In February 2022, Kanabo acquired a national GP online service to improve patient access, signaling a move to enhance last-mile delivery for its medical cannabis products.
What was the outcome of Kanabo's pre-clinical trial in February 2019?
In February 2019, a pre-clinical trial on cannabis active ingredients offered encouraging results for insomnia.

External links